Table 1.
Mean (range) | SD | |
Age (all patients) | 58.5 (19–95) | 14.9 |
Nonfunctional | 58.8 (19–95) | 14.7 |
Functional | 55.2 (19–93) | 16.3 |
N | % | |
Sex | ||
Male | 819 | 55.2 |
Female | 664 | 44.8 |
Race | ||
White | 1247 | 84.1 |
Black | 139 | 9.4 |
Asian | 69 | 4.7 |
Other | 28 | 1.9 |
Stage | ||
Localized | 164 | 11.1 |
Regionally advanced | 307 | 20.7 |
Metastatic | 893 | 60.2 |
Unstaged | 119 | 8.0 |
Grade | ||
1 | 88 | 5.9 |
2 | 77 | 5.2 |
3 | 106 | 7.2 |
4 | 40 | 2.7 |
Not graded | 1172 | 79.0 |
Number of primaries | ||
1 | 1310 | 88.3 |
≥2 | 173 | 11.7 |
Functional statusa | ||
Nonfunctional PETs | 1346 | 90.8 |
Malignant insulinoma | 37 | 2.5 |
Malignant gastrinoma | 63 | 4.2 |
Malignant glucagonoma | 23 | 1.6 |
Malignant VIPoma | 14 | 0.9 |
Based upon histology codes.
SEER, Surveillance, Epidemiology, and End Results.